Clozaril

Novartis is a leading global pharmaceutical company headquartered in Basel, Switzerland, formed in 1996 through the merger of Ciba-Geigy and Sandoz. The company is the original developer and manufacturer of Clozaril (clozapine), a landmark atypical antipsychotic used for treatment-resistant schizophrenia. Novartis operates across a broad spectrum of therapeutic areas, including oncology, immunology, neuroscience, and cardiovascular diseases, with a focus on high-value innovative medicines. While Clozaril is now a legacy product with rights held by various entities regionally (such as HLS Therapeutics in North America), Novartis remains a dominant force in the global CNS market. The company is increasingly pivoting toward advanced technology platforms, including cell and gene therapies, radioligand therapy, and targeted protein degradation.